What are the latest funding news in the longevity market? (March 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market saw a strong wave of funding activity between November 2025 and January 2026, with deals ranging from sub-$2M pre-seed rounds to a $298M Series B.
Therapeutic approaches dominated by count, with mTOR inhibitors, cellular reprogramming, mitochondrial drugs, and regenerative peptides all attracting capital, alongside a growing cluster of diagnostics and wearable biomarker companies.
Geography was notably diverse, with deals closing in the US, UK, Switzerland, and India, suggesting the longevity sector is maturing across multiple innovation ecosystems simultaneously.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Function Health's $298M Series B at a $2.5B valuation dwarfs every other deal in this period combined, highlighting how consumer-facing longevity diagnostics platforms can attract growth-equity scale capital well ahead of clinical proof points.
- 7 out of 12 deals in this period were in the therapeutic category (drugs, cell therapies, reprogramming), confirming that biotech still captures the majority of longevity funding by deal count even as diagnostics and digital tools gain ground.
- Three deals closed on the exact same day (December 18, 2025), suggesting a year-end push by founders and investors to get deals signed before the holiday period.
- Two India-based longevity startups (Biopeak and Decode Age) raised in this window, pointing to an emerging longevity market in India driven by a growing affluent and health-conscious middle class.
- The median deal size in this period (excluding Function Health) was approximately $12.5M, suggesting most longevity companies are still in early-to-mid stage development rather than late-stage scaling.
- Hevolution Foundation appeared as an investor in Aeovian's Series B, continuing its pattern of backing mTOR and aging-pathway pharmacology as part of its mission-driven longevity investment strategy.
- None of the 12 companies disclosed a valuation except Function Health, reflecting the early-stage nature of the market and the reluctance of founders to anchor valuation expectations too early.
- Brain health and neurotech entered the longevity funding landscape via Neurable's $35M Series A, a category that had been underrepresented in prior longevity funding cycles relative to metabolic and cardiovascular aging.
- Red Bull Ventures participating in Liom's Series A extension is a notable signal that consumer lifestyle brands are starting to see longevity wearables as adjacent to their core performance and energy positioning.
In our longevity market deck, we have collected signals proving this market is hot right now
Summary table of the latest funding deals in the longevity market as of March 2026
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the longevity market (we update this list every quarter).
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Biopeak | 29 Jan 2026 | $2.7M | Follow-on | Clinics & Programs |
| Corsera Health | 07 Jan 2026 | $80M | Series A | Therapies & AI Risk Prediction |
| Neurable | 19 Dec 2025 | $35M | Series A | Digital Tools & Neurotech Healthspan |
| Celularity | 18 Dec 2025 | Up to $12M | Financing | Therapies & Regenerative Medicine |
| GlycanAge | 18 Dec 2025 | ~$8.7M | Series A | Diagnostics & Aging Biomarkers |
| Amphix Bio | 18 Dec 2025 | $12.5M | Seed | Therapies & Regenerative Medicine |
| Liom | 18 Dec 2025 | ~$14.5M | Series A Extension | Wearable Biomarkers & Metabolic Health |
| Decode Age | 17 Dec 2025 | $1.7M | Pre-Series A | Diagnostics & Longevity Programs |
| Aeovian Pharmaceuticals | 16 Dec 2025 | $55M | Series B | Therapies & Aging-Pathway Pharmacology |
| Junevity | 03 Dec 2025 | $10M (to $20M total) | Seed Extension | Therapies & Cellular Reprogramming |
| MitoRx Therapeutics | 25 Nov 2025 | ~$7.2M | Pre-Series A | Therapies & Mitochondrial Medicine |
| Function Health | 19 Nov 2025 | $298M | Series B | Diagnostics & Preventive Healthspan Programs |
All the latest funding deals in the longevity market as of March 2026
Biopeak raised $2.7M in a follow-on round in January 2026 to expand its longevity clinic network across India
When was it?
The deal was announced on January 29, 2026.
Who are they?
Biopeak runs longevity and health-optimization clinics in India, combining advanced diagnostics with physician-led, personalized prevention programs.
Geographical focus?
Biopeak is focused on India, with plans to expand its clinic footprint across major Indian cities.
Why do we include them in the longevity market?
Biopeak is explicitly positioned around longevity and healthspan clinical care, placing it squarely in the Clinics and Programs category of the longevity market.
What is the company stage?
Biopeak is in early scaling, with clinics already operating and this funding earmarked for expansion and capability upgrades.
How much did they raise?
Biopeak raised $2.7M in this round.
What round is it?
This was a follow-on round.
Why did they raise?
Biopeak raised to open new clinic locations, upgrade its diagnostics infrastructure, build internal AI tools, and fund clinical research programs.
In our longevity market deck, we help you understand how the market is structured
Corsera Health raised $80M in a Series A in January 2026 to advance its cardiovascular healthspan platform
When was it?
The deal was announced on January 7, 2026.
Who are they?
Corsera Health develops a PCSK9 siRNA therapeutic combined with an AI lifetime cardiovascular risk prediction platform, targeting the prevention of age-linked heart disease.
Geographical focus?
Corsera Health has global ambitions, with early clinical trial activity noted in New Zealand and a broader international development roadmap.
Why do we include them in the longevity market?
Corsera Health directly targets age-linked cardiovascular decline, one of the primary drivers of reduced healthspan, using both a therapeutic and an AI risk platform, placing it in the Therapies and AI Risk Prediction category.
What is the company stage?
Corsera Health is at the clinical stage, having initiated Phase 1 dosing for its lead compound COR-1004 at the time of the announcement.
How much did they raise?
Corsera Health raised $80M in this round.
What round is it?
This was a Series A.
Why did they raise?
Corsera Health raised to fund the clinical development of COR-1004 and to build out its AI-powered lifetime cardiovascular risk prediction platform.
Neurable closed a $35M Series A in December 2025 to scale its everyday brain-computer interface for cognitive health
When was it?
The deal was announced on December 19, 2025.
Who are they?
Neurable builds everyday brain-computer interface technology and a companion app that tracks cognitive states including fatigue, recovery, and focus for ongoing brain health monitoring.
Geographical focus?
Neurable is US-based, headquartered in Boston, with a focus on the American consumer and commercial markets.
Why do we include them in the longevity market?
Neurable is explicitly positioned around brain health and cognitive performance monitoring, a key pillar of healthspan, placing it in the Digital Tools and Neurotech Healthspan category.
What is the company stage?
Neurable is in the growth and scaling phase, using this round to push toward broad commercialization of its BCI platform.
How much did they raise?
Neurable raised $35M in this round.
What round is it?
This was a Series A.
Why did they raise?
Neurable raised to accelerate commercialization of its BCI technology and expand its cognitive health applications and device integrations.
In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
Celularity secured up to $12M in financing in December 2025 to advance its regenerative cell therapy programs
When was it?
The deal was announced on December 18-19, 2025, with binding term sheets signed and an 8-K filing submitted to the SEC.
Who are they?
Celularity is a regenerative and cellular medicine company developing placental-derived cellular therapeutics targeting age-related and degenerative diseases.
Geographical focus?
Celularity is a US-based public company, headquartered in New Jersey.
Why do we include them in the longevity market?
Celularity's stated focus on therapies for age-related and degenerative disease biology places it in the Therapies and Regenerative Medicine category of the longevity market.
What is the company stage?
Celularity is a public-company and later-stage biotech, making this financing transaction different in structure from a typical early-stage VC round.
How much did they raise?
Celularity raised up to $12M, with initial proceeds of approximately $10M referenced in coverage of the term sheets.
What round is it?
This was a structured financing transaction, not a classic VC series round.
Why did they raise?
Celularity raised to fund its strategic priorities around longevity and human performance and to provide operational runway.
GlycanAge raised approximately $8.7M in a Series A in December 2025 to push aging biomarker diagnostics into clinical settings
When was it?
The deal was announced on December 18, 2025.
Who are they?
GlycanAge develops glycan-biomarker diagnostics to measure biological aging and disease risk, with a goal of achieving broad clinical adoption including in hospitals.
Geographical focus?
GlycanAge is UK-based and is targeting broader healthcare adoption across Europe and beyond.
Why do we include them in the longevity market?
GlycanAge is a direct aging biomarker business, placing it in the Diagnostics and Aging Biomarkers category of the longevity market.
What is the company stage?
GlycanAge is in the growth and scaling phase, using this Series A to push its diagnostic tools into mainstream clinical workflows.
How much did they raise?
GlycanAge raised approximately $8.7M (reported as EUR 7.4M) in this round.
What round is it?
This was a Series A.
Why did they raise?
GlycanAge raised to integrate its glycan aging diagnostics into broader clinical workflows, including hospital systems.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Amphix Bio closed a $12.5M seed round in December 2025 to advance its regenerative peptide drug platform toward clinical trials
When was it?
The deal was announced on December 18, 2025.
Who are they?
Amphix Bio is a Northwestern University spinout developing regenerative peptide therapeutics using its STP platform, targeting neurological injury, neurodegeneration, and degenerative conditions.
Geographical focus?
Amphix Bio is US-based, with its roots in Northwestern University's research ecosystem.
Why do we include them in the longevity market?
Amphix Bio is explicitly positioned around increasing healthspan through regenerative medicine, placing it in the Therapies and Regenerative Medicine category.
What is the company stage?
Amphix Bio is at the preclinical stage, working to move its lead candidates toward first-in-human trials.
How much did they raise?
Amphix Bio raised $12.5M in this round.
What round is it?
This was a Seed round.
Why did they raise?
Amphix Bio raised to advance its lead peptide drug candidates into clinical trials and expand its therapeutic pipeline.
Liom extended its Series A to approximately $14.5M in December 2025 to miniaturize its non-invasive biomarker wearable
When was it?
The deal was announced on December 18, 2025.
Who are they?
Liom is a Swiss startup building a non-invasive glucose and biomarker monitoring wearable designed to support long-term metabolic health and resilience.
Geographical focus?
Liom is Switzerland-based with global commercial ambitions.
Why do we include them in the longevity market?
Liom provides continuous metabolic biomarker tracking for long-term healthspan optimization, placing it in the Wearable Biomarkers and Metabolic Health category.
What is the company stage?
Liom is moving from MVP toward early scaling, with this funding focused on engineering miniaturization and productization of its platform.
How much did they raise?
Liom raised approximately CHF 13M (around $14-15M) in this extension round.
What round is it?
This was a Series A extension.
Why did they raise?
Liom raised to fund a breakthrough in sensor miniaturization and accelerate the development of its commercial product.
In our longevity market deck, we will give you useful market maps and grids
Decode Age raised $1.7M in a Pre-Series A in December 2025 to deepen its multi-omics longevity diagnostics and intervention stack
When was it?
The deal was announced on December 17, 2025.
Who are they?
Decode Age is an India-based longevity company selling a stack that combines aging biomarker testing, gut microbiome diagnostics, and science-backed supplements targeting aging pathways.
Geographical focus?
Decode Age is focused on India, with ambitions to grow its longevity offering across the broader market.
Why do we include them in the longevity market?
Decode Age explicitly combines longevity diagnostics with targeted interventions, placing it in the Diagnostics and Longevity Programs category.
What is the company stage?
Decode Age is at early product-market fit, with its commercial offering live and this funding aimed at expanding its science and product stack.
How much did they raise?
Decode Age raised $1.7M in this round.
What round is it?
This was a Pre-Series A.
Why did they raise?
Decode Age raised to deepen its biomarker discovery capabilities, advance multi-omics research and development, and expand its longevity product line.
Aeovian Pharmaceuticals raised $55M in a Series B in December 2025 to advance its selective mTORC1 inhibitor into Phase 2
When was it?
The deal was announced on December 16, 2025.
Who are they?
Aeovian Pharmaceuticals is a Berkeley-based biotech developing selective mTORC1 inhibitors, with its lead program AV078 targeting TSC-related epilepsy in Phase 2 while operating on the mTOR aging pathway.
Geographical focus?
Aeovian is US-based, headquartered in Berkeley, California.
Why do we include them in the longevity market?
Aeovian directly targets mTOR biology, one of the most well-studied and validated aging pathways, placing it in the Therapies and Aging-Pathway Pharmacology category.
What is the company stage?
Aeovian is at the clinical stage, currently running a Phase 2 proof-of-concept study for AV078.
How much did they raise?
Aeovian raised $55M in this round.
What round is it?
This was a Series B.
Why did they raise?
Aeovian raised to fund the completion of its Phase 2 proof-of-concept study and advance its broader mTOR inhibitor platform.
In our longevity market deck, we answer all the common questions from investors and entrepreneurs
Junevity extended its seed to $20M total in December 2025 to push its siRNA cellular reprogramming therapy toward first-in-human studies
When was it?
The deal was announced on December 3, 2025.
Who are they?
Junevity is a San Francisco-based biotech developing "cell reset" therapeutics that use siRNA-driven cellular reprogramming, initially targeting metabolic diseases such as type 2 diabetes and obesity.
Geographical focus?
Junevity is US-based, operating out of San Francisco.
Why do we include them in the longevity market?
Junevity targets core aging hallmarks through cellular reprogramming logic, placing it firmly in the Therapies and Cellular Reprogramming category of the longevity market.
What is the company stage?
Junevity is in the preclinical and IND-enabling phase, targeting first-in-human studies in the second half of 2026.
How much did they raise?
Junevity raised $10M in this extension, bringing its total seed funding to $20M.
What round is it?
This was a seed extension.
Why did they raise?
Junevity raised to advance its lead candidate JUN_01 through IND-enabling work and toward its first-in-human clinical studies, targeted for the second half of 2026.
MitoRx Therapeutics raised approximately $7.2M in a Pre-Series A in November 2025 to advance its mitochondria-targeting obesity drug
When was it?
The deal was announced on November 25, 2025.
Who are they?
MitoRx Therapeutics is an Oxford-based biotech developing mitochondria-targeted metabolic drugs aimed at achieving fat loss while preserving lean mass, framed around metabolic resilience and healthspan.
Geographical focus?
MitoRx is UK-based, operating out of Oxford.
Why do we include them in the longevity market?
MitoRx directly targets mitochondrial function, a key biological lever for healthspan, placing it in the Therapies and Mitochondrial Medicine category.
What is the company stage?
MitoRx is at the preclinical and pre-IND stage, working toward candidate selection and pipeline development.
How much did they raise?
MitoRx raised approximately $7.2M (GBP 5.5M) in this round.
What round is it?
This was a Pre-Series A.
Why did they raise?
MitoRx raised to move its lead compound through candidate selection and support pipeline follow-on development.
In our longevity market deck, we have designed useful charts to give you full market clarity
Function Health raised $298M in a Series B at a $2.5B valuation in November 2025, becoming the largest longevity platform funding round in recent memory
When was it?
The deal was announced on November 19, 2025.
Who are they?
Function Health is a consumer longevity platform that combines broad lab testing and imaging with longitudinal health data and AI-driven insights, focused on early detection and prevention.
Geographical focus?
Function Health is primarily focused on a US consumer rollout.
Why do we include them in the longevity market?
Function Health is explicitly framed around extending healthy years via proactive testing and monitoring, placing it in the Diagnostics and Preventive Healthspan Programs category.
What is the company stage?
Function Health is in the growth phase, with broad consumer traction claimed and this large round designed to fuel further scaling.
How much did they raise?
Function Health raised $298M in this round at a disclosed valuation of $2.5B.
What round is it?
This was a Series B.
Why did they raise?
Function Health raised to scale its platform, roll out AI-powered "medical intelligence" capabilities, and expand consumer access and product offerings.
Related blog posts
- The latest developments shaping the longevity market
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The evolution of funding activity in the longevity market
- The main fundraising trends in the longevity market
- All the recent funding deals in the longevity market
- The startups that have raised the most funding in the longevity market
